Fulton Bank N.A. lowered its stake in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 5.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,094 shares of the medical research company’s stock after selling 169 shares during the period. Fulton Bank N.A.’s holdings in IQVIA were worth $634,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently bought and sold shares of IQV. HighTower Advisors LLC raised its position in IQVIA by 2.4% in the 1st quarter. HighTower Advisors LLC now owns 5,055 shares of the medical research company’s stock valued at $1,168,000 after purchasing an additional 118 shares in the last quarter. Prudential PLC acquired a new stake in IQVIA in the 1st quarter valued at about $741,000. Baird Financial Group Inc. raised its position in IQVIA by 2.3% in the 1st quarter. Baird Financial Group Inc. now owns 99,566 shares of the medical research company’s stock valued at $23,021,000 after purchasing an additional 2,201 shares in the last quarter. Parkside Financial Bank & Trust raised its position in IQVIA by 59.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 388 shares of the medical research company’s stock valued at $90,000 after purchasing an additional 144 shares in the last quarter. Finally, Covestor Ltd raised its position in IQVIA by 82.2% in the 1st quarter. Covestor Ltd now owns 554 shares of the medical research company’s stock valued at $128,000 after purchasing an additional 250 shares in the last quarter. Institutional investors and hedge funds own 86.20% of the company’s stock.
Insider Buying and Selling at IQVIA
In other IQVIA news, insider Kevin C. Knightly sold 4,446 shares of the business’s stock in a transaction on Thursday, February 16th. The stock was sold at an average price of $225.61, for a total transaction of $1,003,062.06. Following the sale, the insider now directly owns 1,973 shares in the company, valued at $445,128.53. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, insider Kevin C. Knightly sold 4,446 shares of the business’s stock in a transaction on Thursday, February 16th. The stock was sold at an average price of $225.61, for a total value of $1,003,062.06. Following the completion of the transaction, the insider now directly owns 1,973 shares of the company’s stock, valued at $445,128.53. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction on Tuesday, February 14th. The shares were sold at an average price of $230.00, for a total value of $230,000.00. Following the completion of the transaction, the insider now owns 17,053 shares of the company’s stock, valued at $3,922,190. The disclosure for this sale can be found here. Company insiders own 1.50% of the company’s stock.
IQVIA Trading Down 2.8 %
IQVIA (NYSE:IQV – Get Rating) last announced its earnings results on Friday, February 10th. The medical research company reported $2.78 earnings per share for the quarter, beating the consensus estimate of $2.76 by $0.02. IQVIA had a return on equity of 31.88% and a net margin of 7.57%. The company had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.71 billion. During the same period last year, the business posted $2.42 EPS. The company’s revenue was up 2.8% on a year-over-year basis. Equities analysts forecast that IQVIA Holdings Inc. will post 9.46 EPS for the current year.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on IQV shares. Cowen started coverage on IQVIA in a research report on Tuesday, December 6th. They set an “outperform” rating on the stock. StockNews.com started coverage on IQVIA in a research report on Thursday. They set a “hold” rating on the stock. SVB Leerink reissued an “outperform” rating on shares of IQVIA in a research report on Friday, January 27th. Cowen started coverage on IQVIA in a research report on Tuesday, December 6th. They set an “outperform” rating and a $251.00 target price on the stock. Finally, Credit Suisse Group reissued an “outperform” rating and set a $265.00 target price on shares of IQVIA in a research report on Monday, February 13th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $256.81.
IQVIA Company Profile
IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm’s life science clients.
Featured Stories
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Get Rating).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
